Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
2.090
-0.175 (-7.73%)
Oct 22, 2025, 4:00 PM EDT - Market closed
Immuron Revenue
In the fiscal year ending June 30, 2025, Immuron had annual revenue of 7.29M AUD with 48.63% growth. Immuron had revenue of 3.29M in the half year ending June 30, 2025, with 169.66% growth.
Revenue (ttm)
7.29M AUD
Revenue Growth
+48.63%
P/S Ratio
3.06
Revenue / Employee
1,041,000 AUD
Employees
7
Market Cap
14.63M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 7.29M | 2.38M | 48.63% |
Jun 30, 2024 | 4.90M | 3.10M | 171.67% |
Jun 30, 2023 | 1.80M | 1.04M | 135.85% |
Jun 30, 2022 | 765.19K | 619.42K | 424.91% |
Jun 30, 2021 | 145.78K | -2.37M | -94.21% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IMRN News
- 5 days ago - Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target - Newsfile Corp
- 9 days ago - Immuron Q1 FY26 YoY growth - GlobeNewsWire
- 14 days ago - Immuron Submits IMM-529 IND to FDA - GlobeNewsWire
- 20 days ago - Immuron Letter to Shareholders – Projects Update - GlobeNewsWire
- 2 months ago - Immuron partners with InvestorHub - GlobeNewsWire
- 3 months ago - Immuron - FY25 global sales exceed projection, up 49% on prior year - GlobeNewsWire
- 5 months ago - Immuron Letter to Shareholders: Projects Update - GlobeNewsWire
- 6 months ago - Immuron Travelan® highest sales in history - GlobeNewsWire